Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Multifaceted Applications of Genetically Modified Micro-organisms: A Biotechnological Revolution

Author(s): Vasavi Basarkar, Sharayu Govardhane and Pravin Shende*

Volume 28, Issue 22, 2022

Published on: 05 July, 2022

Page: [1833 - 1842] Pages: 10

DOI: 10.2174/1381612828666220128102823

Abstract

Background: Genetically modified micro-organisms like bacteria, viruses, algae and fungi are novel approaches used in the field of healthcare due to better efficacy and targeted delivery in comparison to conventional approaches.

Objectives: This review article focuses on the applications of genetically modified micro-organisms in the treatment of cancer, obesity and HIV infection. The gut microbiome causes metabolic disorders, however, the use of genetically modified bacteria alters the gut microbiota and delivers therapeutically effective drugs in the treatment of obesity.

Methods: Enhancement of the therapeutic activity of different micro-organisms is required for multiple treatments in cancer, diabetes, etc., by incorporating their fragments into the microbial filaments with the help of genetic modification approaches. Various methods like amelioration of NAPE synthesis, silica immobilization, polyadenylation and electrochemical are used to integrate the strain into the bacteria and engineer a live virus with a peptide.

Results: The development of novel microbial strains using genetic modifications over core strains offers higher precision, greater molecular multiplicity, better prevention from the degradation of microbes in atmospheric temperature and significant reduction of side effects for therapeutic applications. Moreover, genetically modified micro-organisms are used in multidisciplinary sectors like generation of electricity, purification of water, bioremediation process, etc., indicating the versatility and scope of genetically engineered microbes.

Conclusion: The bioengineered micro-organisms with genetic modifications proved to be advantageous in various conditions like cancer, diabetes, malaria, organ regeneration, inflammatory bowel disease, etc. This article provides insight into various applications of genetically modified microbes in different sectors with their implementation for regulatory approval.

Keywords: Genetically modified, bioengineering, bioremediation, polyadenylation, HIV infection, gut microbiome.

« Previous Next »
[1]
Patyar S, Joshi R, Byrav DS, Prakash A, Medhi B, Das BK. Bacteria in cancer therapy: A novel experimental strategy. J Biomed Sci 2010; 17(1): 21.
[http://dx.doi.org/10.1186/1423-0127-17-21 ] [PMID: 20331869]
[2]
Prakash S, Chang TM. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nat Med 1996; 2(8): 883-7.
[http://dx.doi.org/10.1038/nm0896-883 ] [PMID: 8705857]
[3]
Chen Z, Guo L, Zhang Y, et al. Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J Clin Invest 2014; 124(8): 3391-406.
[http://dx.doi.org/10.1172/JCI72517 ] [PMID: 24960158]
[4]
Pawelek JM, Low KB, Bermudes D. Bacteria as tumour-targeting vectors. Lancet Oncol 2003; 4(9): 548-56.
[http://dx.doi.org/10.1016/S1470-2045(03)01194-X ] [PMID: 12965276]
[5]
Fu J, Astarita G, Gaetani S, et al. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem 2007; 282(2): 1518-28.
[http://dx.doi.org/10.1074/jbc.M607809200 ] [PMID: 17121838]
[6]
Crawfurd KJ, Raven JA, Wheeler GL, Baxter EJ, Joint I. The response of Thalassiosira pseudonana to long-term exposure to increased CO2 and decreased pH. 2011; 6(10): e26695.
[http://dx.doi.org/10.1371/journal.pone.0026695]
[7]
Fang W, Vega-Rodríguez J, Ghosh AK, Jacobs-Lorena M, Kang A, St Leger RJ. Development of transgenic fungi that kill human malaria parasites in mosquitoes. Science 2011; 331(6020): 1074-7.
[http://dx.doi.org/10.1126/science.1199115 ] [PMID: 21350178]
[8]
Blanquet-Diot S, Garrait G, Jarrige J, Alric M. Genetically modified yeasts as a new oral drug delivery system: from in vitro to in vivo validation of the concept. In: Communicating Current Research and Educational Topics and Trends in Applied Microbiology. Formatex, Spain 2007; 378-90.
[9]
Pandey G, Paul D, Jain RK. Conceptualizing “suicidal genetically engineered microorganisms” for bioremediation applications. Biochem Biophys Res Commun 2005; 327(3): 637-9.
[http://dx.doi.org/10.1016/j.bbrc.2004.12.080 ] [PMID: 15649393]
[10]
Lovley DR, Walker DJF. Geobacter protein nanowires. Front Microbiol 2019; 10: 2078.
[http://dx.doi.org/10.3389/fmicb.2019.02078 ] [PMID: 31608018]
[11]
Chatel JM, Langella P, Adel-Patient K, Commissaire J, Wal JM, Corthier G. Induction of mucosal immune response after intranasal or oral inoculation of mice with Lactococcus lactis producing bovine beta-lactoglobulin. Clin Diagn Lab Immunol 2001; 8(3): 545-51.
[http://dx.doi.org/10.1128/CDLI.8.3.545-551.2001 ] [PMID: 11329455]
[12]
Purohit K, Parekh PK, Kern J, et al. Pharmacogenetic manipulation of the nucleus accumbens alters binge‐like alcohol drinking in mice. Alcohol Clin Exp Res 2018; 42(5): 879-88.
[http://dx.doi.org/10.1111/acer.13626 ] [PMID: 29668112]
[13]
McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61(24): 8751-7.
[PMID: 11751395]
[14]
Wing R, Hill J. Successful weight loss maintenance. Annu Rev Nutr 2001; 21: 323-41.
[http://dx.doi.org/10.1146/annurev.nutr.21.1.323]
[15]
Stunkard A. McLAREN-HUME M. The results of treatment for obesity: a review of the literature and report of a series. AMA Arch Intern Med 1959; 103(1): 79-85.
[http://dx.doi.org/10.1001/archinte.1959.00270010085011 ] [PMID: 13605305]
[16]
Kramer FM, Jeffery RW, Forster JL, Snell MK. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes 1989; 13(2): 123-36.
[PMID: 2663745]
[17]
Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int Obes 1989; 13(Suppl. 2): 39-46.
[PMID: 2613427]
[18]
Harris K, Kassis A, Major G, Chou CJ. Is the gut microbiota a new factor contributing to obesity and its metabolic disorders? J Obes 2012; 2012: 879151.
[PMID: 22315672]
[19]
Wang Z, Elizabeth K, Brian JB, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472(7341): 57-63.
[http://dx.doi.org/10.1038/nature09922]
[20]
Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009; 457(7228): 480-4.
[http://dx.doi.org/10.1038/nature07540 ] [PMID: 19043404]
[21]
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444(7122): 1027-31.
[http://dx.doi.org/10.1038/nature05414 ] [PMID: 17183312]
[22]
Faure L, Coulon D, Laroche-Traineau J, et al. Discovery and characterization of an Arabidopsis thaliana N-acylphosphatidyl-ethanolamine synthase. J Biol Chem 2009; 284(28): 18734-41.
[http://dx.doi.org/10.1074/jbc.M109.005744 ] [PMID: 19447891]
[23]
Guo L, Amarnath V, Davies SS. A liquid chromatography-tandem mass spectrometry method for measurement of N-modified phosphatidylethanolamines. Anal Biochem 2010; 405(2): 236-45.
[http://dx.doi.org/10.1016/j.ab.2010.06.027 ] [PMID: 20599652]
[24]
Genetic treatment for blindness may soon be reality. Science Daily 2017. Available from: https://www.sciencedaily.com/releases/2017/11/171111095231.htm.
[25]
Thabuis C, Destaillats F, Lambert DM, et al. Lipid transport function is the main target of oral oleoylethanolamide to reduce adiposity in high-fat-fed mice. J Lipid Res 2011; 52(7): 1373-82.
[http://dx.doi.org/10.1194/jlr.M013391 ] [PMID: 21515921]
[26]
Cluny NL, Keenan CM, Lutz B, Piomelli D, Sharkey KA. The identification of peroxisome proliferator-activated receptor α-independent effects of oleoylethanolamide on intestinal transit in mice. Neurogastroenterol Motil 2009; 21(4): 420-9.
[http://dx.doi.org/10.1111/j.1365-2982.2008.01248.x ] [PMID: 19140957]
[27]
Aviello G, Matias I, Capasso R, et al. Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. J Mol Med (Berl) 2008; 86(4): 413-22.
[http://dx.doi.org/10.1007/s00109-008-0305-7 ] [PMID: 18278475]
[28]
Rodríguez de Fonseca F, Navarro M, Gómez R, et al. An anorexic lipid mediator regulated by feeding. Nature 2001; 414(6860): 209-12.
[http://dx.doi.org/10.1038/35102582 ] [PMID: 11700558]
[29]
Scoot B, Mulrooney H. Regulation of gene expression and cellular localization of cloned K. aerogens urease. J Gen Microbiol 1989; 135: 1769-76.
[PMID: 2693604]
[30]
Malmgren RA, Flanigan CC. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res 1955; 15(7): 473-8.
[PMID: 13240693]
[31]
Liu X, Lagenaur LA, Simpson DA, et al. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob Agents Chemother 2006; 50(10): 3250-9.
[http://dx.doi.org/10.1128/AAC.00493-06 ] [PMID: 17005802]
[32]
Ero-Lambea CP. -Gallego Ruano, A’ngel Fernandez L. Engineered bacteria as therapeutic agents. Curr Opin Biotechnol 2015; 35: 94-102.
[33]
Suzuki A, Nakauchi H, Taniguchi H. Glucagon-like peptide 1 (1-37) converts intestinal epithelial cells into insulin-producing cells. Proc Natl Acad Sci USA 2003; 100(9): 5034-9.
[http://dx.doi.org/10.1073/pnas.0936260100 ] [PMID: 12702762]
[34]
Koizumi M, Doi R, Fujimoto K, et al. Pancreatic epithelial cells can be converted into insulin-producing cells by GLP-1 in conjunction with virus-mediated gene transfer of pdx-1. Surgery 2005; 138(2): 125-33.
[http://dx.doi.org/10.1016/j.surg.2005.06.008 ] [PMID: 16153418]
[35]
Koizumi M, Nagai K, Kida A, et al. Forced expression of PDX-1 induces insulin production in intestinal epithelia. Surgery 2006; 140(2): 273-80.
[http://dx.doi.org/10.1016/j.surg.2006.06.014 ] [PMID: 16904980]
[36]
Majander K, Anton L, Antikainen J, et al. Extracellular secretion of polypeptides using a modified Escherichia coli flagellar secretion apparatus. Nat Biotechnol 2005; 23(4): 475-81.
[http://dx.doi.org/10.1038/nbt1077 ] [PMID: 15806100]
[37]
Catterall K, Robertson D, Hudson S, Teasdale PR, Welsh DT, John R. A sensitive, rapid ferricyanide-mediated toxicity bioassay developed using Escherichia coli. Talanta 2010; 82(2): 751-7.
[http://dx.doi.org/10.1016/j.talanta.2010.05.046 ] [PMID: 20602965]
[38]
Chang PC, Blackwood AC. Simultaneous production of three phenazine pigments by Pseudomonas aeruginosa Mac 436. Can J Microbiol 1969; 15(5): 439-44.
[http://dx.doi.org/10.1139/m69-077 ] [PMID: 4977719]
[39]
Yong YC, Yu YY, Li CM, Zhong JJ, Song H. Bioelectricity enhancement via overexpression of quorum sensing system in Pseudomonas aeruginosa-inoculated microbial fuel cells. Biosens Bioelectron 2011; 30(1): 87-92.
[http://dx.doi.org/10.1016/j.bios.2011.08.032 ] [PMID: 21945141]
[40]
Malvankar NS, Yalcin SE, Tuominen MT, Lovley DR. Visualization of charge propagation along individual pili proteins using ambient electrostatic force microscopy. Nat Nanotechnol 2014; 9(12): 1012-7.
[http://dx.doi.org/10.1038/nnano.2014.236 ] [PMID: 25326694]
[41]
Adhikari R, Malvankar N, Tuominen M, Lovley D. Conductivity of individual Geobacter pili. RSC Advances 2016; 6: 8354.
[http://dx.doi.org/10.1039/C5RA28092C]
[42]
Shih C, Museth AK, Abrahamsson M, et al. Tryptophan-accelerated electron flow through proteins. Science 2008; 320(5884): 1760-2.
[http://dx.doi.org/10.1126/science.1158241 ] [PMID: 18583608]
[43]
Tan Y, Adhikari R, Malvankar N, et al. Synthetic biological protein nanowires with high conductivity. Small Nanowires 2016; 12(33): 4481-5.
[44]
Making Glowing Plants DNA. Genetics 2014. Available from: https://www.popularmechanics.com/home/how-to/a11120/how-tomake- a-plant-glow-17081845/
[45]
Zielenkiewicz U, Cegłowski P. Mechanisms of plasmid stable maintenance with special focus on plasmid addiction systems. Acta Biochim Pol 2001; 48(4): 1003-23.
[http://dx.doi.org/10.18388/abp.2001_3863 ] [PMID: 11995964]
[46]
Lius C, Minton NP, Giaccia AJ, Brown JM. Anti-cancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 2002; (9): 291-6.
[47]
Boyd MR, Gustafson KR, McMahon JB, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 1997; 41(7): 1521-30.
[http://dx.doi.org/10.1128/AAC.41.7.1521 ] [PMID: 9210678]
[48]
Wang L, Chen T, Wang H, et al. Engineered bacteria of MG1363-pMG36e-GLP-1 attenuated obesity-induced by high fat diet in mice. Front Cell Infect Microbiol 2021; 11: 595575.
[http://dx.doi.org/10.3389/fcimb.2021.595575 ] [PMID: 33732656]
[49]
Bai L, Gao M, Cheng X, Kang G, Cao X, Huang H. Engineered butyrate-producing bacteria prevents high fat diet-induced obesity in mice. Microb Cell Fact 2020; 19(1): 94.
[http://dx.doi.org/10.1186/s12934-020-01350-z ] [PMID: 32334588]
[50]
Cunningham C, Nemunaitis J. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Hum Gene Ther 2001; 12(12): 1594-6.
[51]
Ma J, Li C, Wang J, Gu J. Genetically Engineered Escherichia coli Nissle 1917 Secreting GLP-1 Analog Exhibits Potential Antiobesity Effect in High-Fat Diet-Induced Obesity Mice. Obesity (Silver Spring) 2020; 28(2): 315-22.
[http://dx.doi.org/10.1002/oby.22700 ] [PMID: 31970910]
[52]
Delalat B, Sheppard VC, Rasi Ghaemi S, et al. Targeted drug delivery using genetically engineered diatom biosilica. Nat Commun 2015; 6: 8791.
[http://dx.doi.org/10.1038/ncomms9791 ] [PMID: 26556723]
[53]
McInnes SJ, Voelcker NH. Silicon-polymer hybrid materials for drug delivery. Future Med Chem 2009; 1(6): 1051-74.
[http://dx.doi.org/10.4155/fmc.09.90 ] [PMID: 21425994]
[54]
Poulsen N, Berne C, Spain J, Kröger N. Silica immobilization of an enzyme through genetic engineering of the diatom Thalassiosira pseudonana. Angew Chem Int Ed 2007; 46(11): 1843-6.
[http://dx.doi.org/10.1002/anie.200603928 ] [PMID: 17274079]
[55]
Sheppard VC, Scheffel A, Poulsen N, Kröger N. Live diatom silica immobilization of multimeric and redox-active enzymes. Appl Environ Microbiol 2012; 78(1): 211-8.
[http://dx.doi.org/10.1128/AEM.06698-11 ] [PMID: 22057862]
[56]
Gronenborn AM, Clore GM. Structural studies of immunoglobulin binding domains of streptococcal protein G. ImmunoMethods 1993; 2: 3-8.
[http://dx.doi.org/10.1006/immu.1993.1002]
[57]
Saetern AM, Flaten GE, Brandl M. A method to determine the incorporation capacity of camptothecin in liposomes. AAPS PharmSciTech 2004; 5(3): e40.
[http://dx.doi.org/10.1208/pt050340 ] [PMID: 15760073]
[58]
Qiao Y, Yang F, Xie T, et al. Engineered algae: A novel oxygengenerating system for effective treatment of hypoxic cancer. Sci Adv 2020; 6; 6(21): eaba5996.
[http://dx.doi.org/10.1126/sciadv.aba5996]
[59]
Scholte EJ, Ng’habi K, Kihonda J, et al. An entomopathogenic fungus for control of adult African malaria mosquitoes. Science 2005; 308(5728): 1641-2.
[http://dx.doi.org/10.1126/science.1108639 ] [PMID: 15947190]
[60]
Thomas MB, Read AF. Can fungal biopesticides control malaria? Nat Rev Microbiol 2007; 5(5): 377-83.
[http://dx.doi.org/10.1038/nrmicro1638 ] [PMID: 17426726]
[61]
Ghosh AK, Devenport M, Jethwaney D, et al. Malaria parasite invasion of the mosquito salivary gland requires interaction between the Plasmodium TRAP and the Anopheles saglin proteins. PLoS Pathog 2009; 5(1): e1000265.
[http://dx.doi.org/10.1371/journal.ppat.1000265 ] [PMID: 19148273]
[62]
Wang Q, Zhong C, Xiao H. Genetic engineering of filamentous fungi for efficient protein expression and secretion. Front Bioeng Biotechnol 2020; 8: 293.
[http://dx.doi.org/10.3389/fbioe.2020.00293]
[63]
Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289(5483): 1352-5.
[http://dx.doi.org/10.1126/science.289.5483.1352 ] [PMID: 10958782]
[64]
Kapoor N, Liang W, Marbán E, Cho HC. Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18. Nat Biotechnol 2013; 31(1): 54-62.
[http://dx.doi.org/10.1038/nbt.2465 ] [PMID: 23242162]
[65]
Wiese C, Grieskamp T, Airik R, et al. Formation of the sinus node head and differentiation of sinus node myocardium are independently regulated by Tbx18 and Tbx3. Circ Res 2009; 104(3): 388-97.
[http://dx.doi.org/10.1161/CIRCRESAHA.108.187062 ] [PMID: 19096026]
[66]
Jefferson A, Cadet VE, Hielscher A. The mechanisms of genetically modified vaccinia viruses for the treatment of cancer. Crit Rev Oncol Hematol 2015; 95(3): 407-16.
[http://dx.doi.org/10.1016/j.critrevonc.2015.04.001 ] [PMID: 25900073]
[67]
Chulpanova DS, Solovyeva VV, Kitaeva KV, Dunham SP, Khaiboullina SF, Rizvanov AA. 2018; Recombinant viruses for cancer therapy. Biomedicines 6(4): 94.
[http://dx.doi.org/10.3390/biomedicines6040094]
[68]
Buller RM, Chakrabarti S, Moss B, Fredrickson T. Cell proliferative response to vaccinia virus is mediated by VGF. Virology 1988; 164(1): 182-92.
[http://dx.doi.org/10.1016/0042-6822(88)90635-6 ] [PMID: 3363864]
[69]
Schmidt FI, Bleck CK, Mercer J. Poxvirus host cell entry. Curr Opin Virol 2012; 2(1): 20-7.
[http://dx.doi.org/10.1016/j.coviro.2011.11.007 ] [PMID: 22440962]
[70]
Guse K, Sloniecka M, Diaconu I, et al. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol 2010; 84(2): 856-66.
[http://dx.doi.org/10.1128/JVI.00692-09 ] [PMID: 19906926]
[71]
Bhattacharya S. Genetically-modified virus explodes cancer cells. Molecular Therapy Biotechnology Regulatory Authority of India 2004; 2004.
[72]
Al Yaghchi C, Zhang Z, Alusi G, Lemoine NR, Wang Y. Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. Immunotherapy 2015; 7(12): 1249-58.
[http://dx.doi.org/10.2217/imt.15.90 ] [PMID: 26595180]
[73]
Yamamoto Y, Nagasato M, Yoshida T, Aoki K. Recent advances in genetic modification of adenovirus vectors for cancer treatment. Cancer Sci 2017; 108(5): 831-7.
[http://dx.doi.org/10.1111/cas.13228 ] [PMID: 28266780]
[74]
Ossola A. 2015. FDA approves use of engineered herpes virus to treat cancer popular science Available from: https://www.popsci.com
[75]
Leja J, Yu D, Nilsson B, et al. Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells. Gene Ther 2011; 18(11): 1052-62.
[http://dx.doi.org/10.1038/gt.2011.54 ] [PMID: 21490682]
[76]
Amato RJ, Shingler W, Goonewardena M, et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother 2009; 32(7): 765-72.
[http://dx.doi.org/10.1097/CJI.0b013e3181ace876 ] [PMID: 19561532]
[77]
Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003; 5(8): 690-9.
[http://dx.doi.org/10.1002/jgm.397 ] [PMID: 12898638]
[78]
Hui EP, Taylor GS, Jia H, et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res 2013; 73(6): 1676-88.
[http://dx.doi.org/10.1158/0008-5472.CAN-12-2448 ] [PMID: 23348421]
[79]
Oudard S, Rixe O, Beuselinck B, et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 2011; 60(2): 261-71.
[http://dx.doi.org/10.1007/s00262-010-0935-9 ] [PMID: 21069322]
[80]
Duggan MC, Jochems C, Donahue RN, et al. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas. Cancer Immunol Immunother 2016; 65(11): 1353-64.
[http://dx.doi.org/10.1007/s00262-016-1893-7 ] [PMID: 27581603]
[81]
Yeh MT, Bujaki E, Dolan PT, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe 2020; 27(5): 736-751.e8.
[http://dx.doi.org/10.1016/j.chom.2020.04.003]
[82]
Bell GJ, Loop MS, Mvalo T, et al. Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi. BMC Public Health 2020; 20(1): 910.
[83]
Ota MO, Odutola AA, Owiafe PK, et al. 2011; Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med 3; 88: 88ra56.
[http://dx.doi.org/10.1126/scitranslmed.3002461]
[84]
Nemunaitis J, Meyers T, Senzer N, et al. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 2006; 13(6): 1185-91.
[http://dx.doi.org/10.1016/j.ymthe.2006.01.013 ] [PMID: 16581300]
[85]
Genetically modified organisms: Applications and decisions information about the release of genetically modified organisms (GMOs) for research purposes application and consent process. Dept. of Environment, Food & Rural Affairs, GOV.UK 2018.
[86]
Law Library of Congress (U.S.). Restrictions on genetically modified organisms. Washington: D.C. The Law Library of Congress, Global Legal Research Center 2014.
[87]
Malvankar NS, Vargas M, Nevin KP, et al. Tunable metallic-like conductivity in microbial nanowire networks. Nat Nanotechnol 2011; 6(9): 573-9.
[http://dx.doi.org/10.1038/nnano.2011.119 ] [PMID: 21822253]
[88]
Malvanka N, Vargas M, Nevin K, et al. Aromatic amino acids required for pili conductivity and long-range extracellular electron transport in Geobacter sulfurreducens. Bio 2013; 4(2): 00105-13.
[89]
Guidance 21: Medicines produced by genetic manipulation, 2013. Available from: https://www.tga.gov.au/sites/default/files/pm-argpm-guidance-21.pdf

Rights & Permissions Print Cite
Article Metrics
26
1
© 2024 Bentham Science Publishers | Privacy Policy